Conclusions
NSCLC
NSCLC
Our work reveals that in trials of novel systemic treatments in patients with metastatic NSCLC, improvements in QoL correlate with PFS advantage, particularly for EGFR and ALK inhibitors. Further collaboration between academic institutions and industries is needed to improve the assessment methodologies of QoL in clinical trials, as well as the way the results are reported.